1. Home
  2. NMZ vs ERAS Comparison

NMZ vs ERAS Comparison

Compare NMZ & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

NMZ

Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

HOLD

Current Price

$10.67

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$13.60

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NMZ
ERAS
Founded
2003
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.0B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NMZ
ERAS
Price
$10.67
$13.60
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$5.78
AVG Volume (30 Days)
453.1K
3.7M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
5.08%
N/A
EPS Growth
N/A
16.87
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.36
$1.01
52 Week High
$11.34
$14.17

Technical Indicators

Market Signals
Indicator
NMZ
ERAS
Relative Strength Index (RSI) 65.24 76.07
Support Level $10.49 $1.27
Resistance Level $10.66 N/A
Average True Range (ATR) 0.06 0.73
MACD 0.00 -0.07
Stochastic Oscillator 66.67 78.30

Price Performance

Historical Comparison
NMZ
ERAS

About NMZ Nuveen Municipal High Income Opportunity Fund $0.01 par value per share

Nuveen Municipal High Income Opp Fund is a diversified, closed-end management investment company. The company's investment objectives is to provide current income exempt from regular federal income tax by investing predominantly in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories. It seeks to provide attractive monthly tax-free income, portfolio diversification and attractive after tax total returns. The fund invests in municipal securities that are exempt from federal income taxes.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

Share on Social Networks: